Partin tables: Past and present

BJU International

Volumn 92, Issue 1, 2003, Pages 7-11

  Khan, M A ^a   Partin, A W ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Nomograms; Partin tables; Prostate adenocarcinoma

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

CANCER EPIDEMIOLOGY; CANCER SCREENING; CANCER STAGING; CLINICAL FEATURE; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; HISTOPATHOLOGY; HUMAN; NOMOGRAM; PREDICTION; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATECTOMY; PROTEIN BLOOD LEVEL; SHORT SURVEY; TREATMENT INDICATION; TUMOR BIOPSY; VALIDATION PROCESS;

HUMANS; MALE; NEOPLASM STAGING; PREOPERATIVE CARE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; URINARY BLADDER NEOPLASMS;

EID: 0037826012     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.2003.04275.x     Document Type: Short Survey

References (13)

1. Partin AW, Yoo JK, Carter HB et al. The use of prostate-specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993; 150: 110-4
2. Partin AW, Kattan MW, Subong EN et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997; 277: 1445-51
3. Blute ML, Bergstralh EJ, Partin AW et al. Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer. J Urol 2000; 164: 1591-5
4. Carter HB, Coffey DS. Prostate cancer, the magnitude of the problem in the United States. In Coffey DS, Resnick MI, Dorr FA, Karr JP eds, A Multidisciplinary Analysis of Controversies in the Management of Prostate Cancer. Chapt 1. New York: Plenum Press, 1988: 1-7
5. Carter HB, Partin AW. Diagnosis and staging of prostate cancer. In Walsh PC, Retik AB, Vaughan ED et al. eds. Campbell's Urology. 8th edn, Vol. IV. Chapt 89. New York: Elsevier Science, 2002: 3055-79
6. Ercole CJ, Lange PH, Mathisen M, Chiou RK, Reddy PK, Vessella RL. Prostate-specific antigen and prostatic acid phosphatase in the monitoring and staging of patients with prostatic cancer. J Urol 1987; 138: 1181-4
7. Rainwater LM, Morgan WR, Klee GG, Zincke H. Prostate-specific antigen testing in untreated and treated prostatic adenocarcinoma. Mayo Clin Proc 1990; 65: 1118-26
8. Catalona WJ, Smith DS, Ratliff TL et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991; 324: 1156-61
9. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987; 317: 909-16
10. Partin AW, Carter HB, Chan DW et al. Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol 1990; 143: 747-52
11. Gleason DF. The Veterans Administration Cooperative Urological Research Group. Histological grading and clinical staging of prostatic carcinoma. In Tannenbaum M ed. Urologic Pathology: the Prostate. Philadelphia: Lea & Febiger, 1977: 171-97
12. Stamey TA, Donaldson AN, Yemoto CE et al. Histological and clinical findings in 896 consecutive prostates treated only with radical retropubic prostatectomy: Epidemiologic significance of annual changes. J Urol 1998; 160: 2412-7
13. Partin AW, Mangold LA, Lamm DM et al. Contemporary update of prostate cancer staging nomograms (Partin tables) for the new millennium. Urology 2001; 58: 843-8